Advancements in stem cell-derived embryo models (SCBEM) offer unprecedented insights into early human development but raise complex regulatory and ethical issues globally. Recent recommendations emphasize enhanced oversight to navigate these challenges responsibly. Countries like Australia classify blastocyst-like structures as embryos, providing a framework for ethical standards, while debates continue elsewhere regarding research scope and governance to balance scientific progress with public trust.